Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
772.700.06%
QQQ
717.030.09%
BTC/USD
81020.990.3139%
DIA
536.820.02%
GLD
410.870.16%
TLT
82.140.09%

Olema Pharmaceuticals inc

OLMANASDAQ
Trade with Public
Trade with Public
$10.73
-0.1-0.92%
At close: Sep 3, 5:00 PM EST
$10.73
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Olema Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Olema Pharmaceuticals (OLMA).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

10Buy
Consensus RatingBuy# Analysts10Avg. Consensus PT$43Upside to Avg. PT+297.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026JP MorganAnupam RamaPT CutOverweight$52→$46
Aug 11, 2026CitigroupYigal NochomovitzPT CutBuy$62→$59
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target from $52 to $46.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36

HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $36.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $35.
Benzinga Newsdesk

PRO
Wolfe Research Initiates Coverage On Olema Pharmaceuticals with Peer Perform Rating

Wolfe Research analyst Kalpit Patel initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Peer Perform rating.
Benzinga Newsdesk

PRO
Jefferies Assumes Olema Pharmaceuticals at Buy, Lowers Price Target of $40

Jefferies analyst Dennis Ding assumes Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and lowers Price Target of $40.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved